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The AMP-activated protein kinase (AMPK) is an evolutionarily conserved sensor of cellular energy status, and recent data
demonstrate that it also plays a critical role in systemic energy balance. AMPK integrates nutritional and hormonal signals
in peripheral tissues and the hypothalamus. It mediates effects of adipokines (leptin, adiponectin, and possibly resistin)
in regulating food intake, body weight, and glucose and lipid homeostasis. AMPK is regulated by upstream kinases of
which the tumor suppressor, LKB1, is the first to be identified. Complex signaling networks suggest that AMPK may
prevent insulin resistance, in part by inhibiting pathways that antagonize insulin signaling. Through signaling, metabolic,
and gene expression effects, AMPK enhances insulin sensitivity and fosters a metabolic milieu that may reduce the risk
for obesity and type 2 diabetes.Introduction
Over millennia, mammalian evolution selected for genes that
allowed for survival during times of famine or drought. In mod-
ern society, this genetic constellation has become maladaptive
owing to the fact that industrialization has made food supply
more abundant and reduced the need to be physically active.
Hence, the prevalence of obesity and its associated morbidi-
ties (including type 2 diabetes, hypertension, cardiovascular
disease, and the metabolic syndrome) continues to climb. Un-
derstanding the fundamental biology of energy balance is
essential to developing new approaches to “stay the tide” of
these metabolic diseases. Historically, the AMP-activated pro-
tein kinase (AMPK) pathway was viewed primarily as a sensor
and regulator of energy balance at the cellular level. Indeed,
the fact that orthologs of AMPK are found in single celled eu-
karyotes such as the yeast Saccharomyces cerevisiae and the
primitive protist Giardia lamblia (Carling, 2004; Hardie et al.,
2003) is consistent with this being the function for which it orig-
inally evolved. However, during the last three years, it has be-
come apparent that in mammals, AMPK is also involved in the
fundamental regulation of energy balance at the whole body
level by responding to hormonal and nutrient signals in the
central nervous system and peripheral tissues that modulate
food intake and energy expenditure.
Structure and regulation of AMPK
AMPK is the downstream component of a kinase cascade that
acts as a sensor of cellular energy charge, being activated by
rising AMP coupled with falling ATP. Because of the near equi-
librium reaction catalyzed by adenylate kinase (2ADP4 ATP +
AMP), the cellular AMP:ATP ratio varies approximately as the
square of the ADP:ATP ratio, making the former a more sensi-
tive index of energy status. AMPK exists as a heterotrimerCELL METABOLISM : JANUARY 2005 · VOL. 1 · COPYRIGHT © 2005 ELcomprising a catalytic α subunit and regulatory β and γ sub-
units. In mammals, each subunit is encoded by multiple genes
(α1, α2, β1, β2, γ1, γ2, γ3) (Carling, 2004; Hardie et al., 2003),
with splice variants and alternative promoters further increas-
ing the complexity. In mammalian cells, AMP allosterically acti-
vates the complex, although this has not yet been convincingly
demonstrated with orthologs from lower eukaryotes. In mam-
mals, AMP also promotes activation of AMPK by stimulating
phosphorylation of the kinase domain at a critical threonine
residue in the activation loop (Thr-172) by an upstream ki-
nase(s) whose identity is discussed later. The nucleotide also
inhibits dephosphorylation of Thr-172 by protein phospha-
tases; the effects of AMP on both phosphorylation and
dephosphorylation appear to be due to binding of the ligand
to the substrate, AMPK, and not to the upstream kinase or
phosphatase. The fact that AMP activates AMPK by three
mechanisms, rather than one, means that the system is exqui-
sitely sensitive to small changes in cellular AMP (reviewed in
Hardie et al., 2003). All three effects of AMP on the AMPK sys-
tem (allosteric activation, phosphorylation, and inhibition of de-
phosphorylation) are antagonized by high concentrations of
ATP, so the system essentially monitors changes in the cellular
AMP:ATP ratio.
What are the functions of the three subunits
of the complex?
The α subunit contains an N-terminal kinase domain and a
C-terminal domain involved in complex formation. The β sub-
units contain conserved C-terminal domains that are sufficient
on their own to form a complex with α and γ (Hudson et al.,
2003). The β subunits in all eukaryotes also contain a carbohy-
drate binding domain that is related to domains found in en-
zymes that metabolize the α1/6 branch points in α1/4
linked glucans, such as starch and glycogen (Hudson et al.,SEVIER INC. DOI:10.1016/j.cmet.2004.12.003 15
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mains unclear, although it causes association of AMPK com-
plexes with glycogen particles, where one physiological target,
i.e., glycogen synthase, resides. In both rat and human muscle
there is also evidence that a high cellular glycogen content re-
presses activation of AMPK (Wojtaszewski et al., 2002, 2003).
This raises the intriguing possibility that, as well as being able
to sense the immediate availability of energy in the form of ATP,
the AMPK system can also sense its more medium-term avail-
ability in the form of glycogen, although this phenomenon has
not yet been reproduced in a cell-free system.
The γ subunits of AMPK contain four repeats of a sequence
motif of about 60 residues first recognized by Bateman (Bate-
man, 1997) and originally termed a CBS domain. These occur
in a number of proteins in archaea, bacteria, and eukaryotes,
and since the functional unit is a dimer, Kemp (Kemp, 2004)
has suggested the term “Bateman domain” to describe the
structure formed by two tandem CBS motifs. Unusually, the γ
subunits of AMPK contain four repeats, forming two tandem
Bateman domains. Each of these domains binds one molecule
of AMP or ATP in a mutually exclusive manner (Scott et al.,
2004), consistent with the findings that high concentrations of
ATP antagonize activation of AMPK by AMP. Constructs con-
taining both Bateman domains bind two molecules of AMP or
ATP with strong positive cooperativity, which may be a further
mechanism to increase the sensitivity of the AMPK system to
small changes in nucleotide levels.
Functional information from naturally occurring
mutations in AMPK
Interestingly, six different point mutations in the gene encoding
the γ2 subunit isoform, four affecting the N-terminal Bateman
domain and two affecting the C-terminal domain, cause a he-
reditary heart disease in humans, i.e., Wolff-Parkinson-White
syndrome (WPWS), which is usually associated with hypertro-
phic cardiomyopathy (HCM) (Scott et al., 2004). These mut-
ations have similar effects on binding of AMP to the isolated
Bateman domains and on activation of the heterotrimeric com-
plex by AMP (Daniel and Carling, 2002; Scott et al., 2004), pro-
viding strong evidence that the Bateman domains provide the
regulatory nucleotide binding sites in the AMPK complex. How
these mutations cause WPWS and HCM is a complex issue
that remains the subject of intense investigation. All the mut-
ations interfere with AMP activation of AMPK. However, there
is evidence, albeit indirect, that some mutations also increase
the basal phosphorylation and activation of AMPK (Arad et al.,
2002; Minokoshi et al., 2004). If correct, this would help explain
why the mutations are dominant and appear to act as gain-of-
function mutations, as does a similar mutation in γ3 in pigs
(R225Q, equivalent to R302Q in γ2) (Milan et al., 2000). The
equivalent mutation in γ1 (R70Q) has not yet been found to
occur naturally but appears to be more active than the wild-
type under basal conditions when expressed in cultured cells
(Hamilton et al., 2001).
Activators of AMPK
Cellular stresses
The AMPK system is activated by a large variety of cellular
stresses that deplete ATP (Carling, 2004; Hardie, 2004; Hardie
et al., 2003) including metabolic poisons such as inhibitors of
the tricarboxylic acid cycle (arsenite), the respiratory chain
(antimycin A, azide), or the mitochondrial ATP synthase (oligo-16mycin), as well as uncouplers of oxidative phosphorylation
such as dinitrophenol. AMPK is also activated by pathological
stresses such as glucose deprivation, ischemia, hypoxia, oxi-
dative stress, and hyperosmotic stress. With the exception of
the latter (Fryer et al., 2002), all of these are associated with
increases in the cellular AMP:ATP ratio. The finding that AMPK
is activated by glucose deprivation is particularly interesting
because extensive genetic studies show that the budding
yeast ortholog of AMPK, i.e., the SNF1 complex, is required for
the survival response to glucose starvation (Hardie et al., 1998).
Exercise and contraction
The pathological or pharmacological stresses described above
interfere with ATP production, but a metabolic stress that acti-
vates AMPK under more physiological conditions by increasing
ATP consumption is exercise (Winder and Hardie, 1996) or con-
traction (Hutber et al., 1997) in skeletal muscle. The degree of
AMPK activation depends on the intensity of exercise and is
thought to be induced by changes in AMP/ATP and creatine/
phosphocreatine ratios (reviewed in Aschenbach et al., 2004).
However, exercise also activates AMPK in liver and adipose
tissue, which may result, in part, from exercise-induced release
of molecules such as interleukin 6 from muscle (Kelly et al.,
2004) and also from systemic alterations in substrate availabil-
ity. AMPK activation in response to exercise acutely inhibits
ATP-consuming pathways and activates carbohydrate and
fatty acid metabolism to restore ATP levels in muscle. It also
plays a role in the adaptive response of muscle to endurance
training by altering muscle fuel reserves and expression of ex-
ercise-responsive genes (Aschenbach et al., 2004). Increased
physical activity reduces the risk of developing insulin resis-
tance and Type 2 diabetes in susceptible human populations
(Hu et al., 2001), and AMPK activation may account for at least
some of the beneficial effects of exercise such as increased
fatty acid oxidation (Merrill et al., 1997; Aschenbach et al.,
2004), increased mitochondrial biogenesis (Zong et al., 2002),
and possibly glucose uptake (Mu et al., 2001), although its role
in the latter has become controversial (see below).
Antidiabetic drugs
Further interest in the potential role of the AMPK pathway in
the treatment of Type 2 diabetes was generated by findings
that AMPK is activated indirectly by metformin (Zhou et al.,
2001) and thiazolidinediones (Fryer et al., 2002), widely used
treatments for Type 2 diabetes. Both metformin (El-Mir et al.,
2000) and thiazolidinediones (Brunmair et al., 2004) inhibit
Complex I of the respiratory chain, and this may be how they
activate AMPK. However, while thiazolidinediones (Fryer et al.,
2002) cause increases in the cellular AMP:ATP ratio, this has
not been demonstrated for metformin (Fryer et al., 2002; Haw-
ley et al., 2002). Thiazolidinediones also increase plasma adi-
ponectin and decrease plasma resistin levels, which could con-
tribute to the indirect effects on AMPK activity (see below).
Most of the actions of thiazolidinediones are thought to be ex-
plained by another target, the PPAR-γ, a nuclear receptor.
While there is currently no other known target for metformin,
more studies are needed to clarify how critical the activation of
AMPK is for the therapeutic effects of these drugs.
Target proteins and pathways for the AMPK
system—Role in systemic energy balance
In general, activation of AMPK switches on alternate catabolic
pathways that generate ATP while switching off ATP-consum-CELL METABOLISM : JANUARY 2005
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achieves these effects both by rapid, direct phosphorylation of
metabolic enzymes and via more long-term effects on gene
and protein expression. Some of its overall effects on metabo-
lism are summarized in Figure 1 and target proteins and path-
ways downstream of AMPK are listed in Table 1 and Supple-
mental Table 1 (which is more extensive with references) and
reviewed in Carling (2004), Hardie (2004) and Hardie et al.
(2003). In this article we will focus on recent findings regarding
the role of AMPK in whole body energy balance.
Obesity results from an imbalance between energy intake
and expenditure. It has long been known that increased adi-
posity is associated with insulin resistance and a markedly
increased risk of developing type 2 diabetes, but only recently
have data suggested that AMPK may play a role. AMPK affects
energy intake, utilization, and storage through regulation ofFigure 1. Role of AMP-activated protein kinase (AMPK) in the control of whole-body energy homeostasis
Activation of AMPK in many tissues switches off ATP-consuming processes while switching on catabolic processes that generate ATP. Some key metabolic effects are
shown. The adipocyte-derived hormones leptin and adiponectin, as well as exercise, activate AMPK in skeletal muscle, stimulating fatty acid oxidation. Leptin’s
activation of AMPK in skeletal muscle involves the hypothalamic-sympathetic nervous system (SNS) axis. Adiponectin also activates AMPK in liver, increasing fatty
acid oxidation and reducing gluconeogenesis, and in adipocytes, where the downstream biologic pathway has not been studied. Resistin inhibits AMPK in liver. AMPK
inhibits insulin secretion from pancreatic β cells.
*Insulin inhibits AMPK activation in ischemic heart and hypothalamus, whereas it has no effect on AMPK in skeletal muscle or adipocytes. In hypothalamus, AMPK
activity plays a role in regulation of food intake and body weight (see Figure 3).CELL METABOLISM : JANUARY 2005food intake and substrate flux and metabolism (Figure 1). It
regulates many molecules and pathways in skeletal muscle,
heart, adipose tissue, liver, pancreatic β cells, and the brain
that control glucose and lipid uptake, storage, and utilization
(see Table 1, Supplemental Table 1, and Figure 1) (Hardie et al.,
2003). A major recent advance has been the discovery that
AMPK elicits this regulation in part by responding to hormonal
and nutrient signals.
One pathway that is central to the integrated effects of
AMPK in peripheral tissues to reduce the risk for obesity and
insulin resistance is the stimulation of fatty acid oxidation (Fig-
ure 2). AMPK phosphorylates acetyl CoA carboxylase (ACC), a
rate-controlling step in the conversion of acetyl-CoA to malonyl
CoA. This phosphorylation inhibits the activity of ACC, which
results in decreased malonyl CoA levels. Malonyl CoA inhibits
carnitine:palmitoyl-CoA transferase-1 (CPT1), a rate-limiting17
R E V I E WTable 1. Examples of targets of AMPK and their biologic effects*
Organ/cell type Immediate outcome Biologic end result
Glucose homeostasis — Primary targets
Muscle glycogen synthase enzyme activity Y glycogen synthesis Y
Heart 6-phosphofructo-2-kinase enzyme activity [ glycolysis [
C2C12 cells insulin receptor substrate-1 PI-3-kinase binding [ insulin sensitivity [?
Liver transcription factor ChREBP DNA binding Y pyruvate kinase expression Y
Lipid metabolism — Primary targets
Liver acetyl-CoA carboxylase-1/α enzyme activity Y fatty acid synthesis Y
Muscle acetyl-CoA carboxylase-2/β enzyme activity Y fatty acid oxidation [
Liver HMG-CoA reductase enzyme activity Y cholesterol synthesis Y
Adipose tissue hormone-sensitive lipase activation by PKA Y lipolysis Y
Mitochondrial biogenesis/function — No known primary targets. Secondary targets include:
Muscle transcription factor NRF1 DNA binding [ mitochondrial biogenesis [
Muscle UCP3 expression[ mitochondrial proton leak [
Muscle co-activator PGC-1α expression [ mitochondrial biogenesis [
Other (examples) — Primary targets
Epithelia CFTR channel activity Y Cl-/fluid secretion Y
Heart endothelial NO synthase enzyme activity [ NO production [
Cultured cells TSC2 inhibition of TOR [ protein synthesis/cell growth Y
Cultured cells TOR phosphorylation of S6 kinase Y protein synthesis/cell growth Y?
Cultured cells co-activator p300 coactivator-receptor binding Y gene expression Y
“Primary targets” are direct targets for AMPK where the phosphorylation site(s) have been identified. “Secondary targets” are either regulated indirectly or the direct
target remains unclear.
*See Supplemental Table 1 for multiple other secondary targets involved in glucose and lipid metabolism and other biologic processes. Supplemental Table l contains
specific references for all targets.Figure 2. Model for the stimulatory effect of AMPK on fatty-acid oxidation in
muscle
Exercise and adipokines (leptin and adiponectin) result in activation of AMPK,
which phosphorylates and inhibits acetyl CoA carboxylase (ACC) activity. This
reduces malonyl CoA synthesis, activating carnitine palmitoyl transferase (CPT1)
and thereby increasing mitochondrial import and oxidation of long-chain acyl-
CoA fatty acids in muscle. Leptin activates AMPK in muscle through two distinct
mechanisms: one is a direct effect through the leptin receptor in muscle and the
other is mediated by the hypothalamic-sympathetic nervous system (SNS) axis
through α adrenergic receptors in muscle (Minokoshi et al., 2002).18step for the entry of long-chain fatty acyl-CoA into mito-
chondria for oxidation. A fall in malonyl CoA levels disinhibits
CPT1, resulting in increased fatty acid oxidation. This pathway
is thought to be central to the effects of AMPK to reduce lipid
stores in muscle and liver and hence to its insulin-sensitizing
effects.
AMPK mediates metabolic effects of adipokines
Another major advance in understanding metabolism over the
last decade has been the recognition that adipose tissue is an
endocrine organ that secretes a large number of hormones,
cytokines, and lipids that have systemic effects on processes
such as glucose and lipid homeostasis, body weight regula-
tion, blood pressure, and immune function (Kershaw and Flier,
2004). These molecules have been termed adipokines and
many of their metabolic actions are mediated by AMPK.
Leptin
Leptin is an adipocyte-secreted hormone that plays a pivotal
role in regulation of food intake, energy expenditure, body
weight, and neuroendocrine function (Friedman and Halaas,
1998). Leptin stimulates fatty acid oxidation (Minokoshi et al.,
2002; Muoio et al., 1997) and glucose uptake (Haque et al.,
1999; Kamohara et al., 1997) and prevents lipid accumulation
in nonadipose tissues, which can otherwise lead to functional
impairments (lipotoxicity) (Unger, 2002). While many of leptin’s
effects are mediated through the Jak-Stat pathway leading to
changes in gene transcription, many key metabolic effects of
leptin take place too rapidly to be ascribed to changes in gene
transcription. Hence, investigators sought another signaling
pathway mediating leptin’s metabolic effects. Leptin was found
to selectively stimulate phosphorylation and activation of the
α2 catalytic subunit of AMPK (α2 AMPK) in skeletal muscleCELL METABOLISM : JANUARY 2005
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transient activation of AMPK by leptin directly at the level of
muscle and a more sustained activation lasting at least 6 hr
after a single injection of leptin (Figure 2). The latter is mediated
through the hypothalamic-sympathetic nervous system (SNS)
axis and α adrenergic receptors in muscle (Minokoshi et al.,
2002). The direct effect may be due to increased AMP levels in
muscle, whereas no change in muscle AMP concentrations
was detected with the indirect effect. Hence, it could result
from activation of upstream AMPK kinases (see below) or an-
other novel mechanism. In parallel with AMPK activation, leptin
suppresses ACC2 activity, thereby stimulating fatty acid oxida-
tion in muscle (Figure 2). AMPK activation appears to be critical
for leptin’s effects on fatty acid oxidation in muscle (Minokoshi
et al., 2002). AMPK also inhibits lipogenesis in the liver. To the
extent that obesity and type 2 diabetes are associated with
“ectopic” deposition of triglycerides in nonadipose tissues and
resistance to leptin action (Unger, 2002), AMPK activators may
bypass leptin resistance and reduce insulin resistance and the
risk for type 2 diabetes. In addition to mediating leptin’s action
in skeletal muscle, AMPK is also a key regulator of leptin action
in the hypothalamus (see below).
Adiponectin
Adiponectin is an adipocyte-secreted molecule that circulates
in macromolecular complexes, increases fatty acid oxidation
and glucose uptake, inhibits gluconeogenesis, and prevents
atherosclerosis by direct effects on the vasculature (Goldstein
and Scalia, 2004). Adiponectin stimulates AMPK phosphoryla-
tion and activity in muscle and liver in vivo and in vitro (Ya-
mauchi et al., 2002). In muscle, the activation of AMPK is nec-Figure 3. Regulation of AMPK activity in the hypo-
thalamus by hormonal and nutrient signals
Peripheral hormones that control food intake modu-
late the activity of hypothalamic AMPK. The anorexi-
genic hormones insulin and leptin decrease AMPK
activity in hypothalamic nuclei including arcuate nu-
cleus (ARC) and paraventricular nucleus (PVN).
Conversely, the stomach-derived orexigenic hor-
mone, ghrelin, increases hypothalamic AMPK. Nut-
ritional state also modulates hypothalamic AMPK;
fasting or hypoglycemia increases hypothalamic
AMPK while refeeding or hyperglycemia decreases
AMPK activity. α-lipoic acid decreases hypothala-
mic AMPK activity and food intake. Manipulation of
the melanocortin pathway in the hypothalamus al-
ters AMPK activity. The orexigenic peptide Agouti-
related protein (AgRP), an antagonist of melanocor-
tin 4 receptor (MC4R), increases AMPK activity in
the PVN while the anorexigenic melanocortin ago-
nist (MT-II) decreases PVN AMPK activity.
*A “hypoglycemic-like state” was induced by injec-
tion of 2-deoxyglucose.
Inset: Leptin’s anorexigenic action in the hypothala-
mus (shown in red) involves inhibition of AMPK and
activation of STAT3 and PI3K activity in the ARC and
the PVN. Decreased AMPK activity results in inhibi-
tion of Neuropeptide Y (NPY)/AgRP neurons, while
increased Stat3, and possibly PI3K, activities both
inhibit NPY/AgRP neurons and activate Proopiomel-
anocortin (POMC) neurons in the ARC, which pro-
ject to the PVN. Leptin inhibition of AMPK in
the PVN requires the MC4R, suggesting that leptin’s action is mediated by projections of POMC neurons from the ARC, but a direct effect of leptin on AMPK in the
PVN is possible. Abbreviations: 3V, third ventricle;NPY, neuropeptide Y; AgRP, agouti related peptide; PI3K, phosphoinositide 3-kinase.CELL METABOLISM : JANUARY 2005essary for adiponectin’s effects on fatty acid oxidation and
glucose transport and is associated with increased AMP levels.
In liver, AMPK activation is necessary for the effects on inhibi-
tion of PEPCK and glucose 6 phosphatase expression and he-
patic glucose production (Yamauchi et al., 2002). Furthermore,
blocking the effect of adiponectin to activate AMPK in liver
using a dominant-negative AMPK abrogates the glucose
lowering effect of adiponectin (Yamauchi et al., 2002). Adipo-
nectin also activates AMPK in isolated adipocytes, although
the biologic effect is unknown (Wu et al., 2003). Thus, the
AMPK pathway is critical for the metabolic- and insulin-sensi-
tizing actions of adiponectin as well as leptin.
Resistin
Resistin is a hormone secreted by adipocytes in rodents and
possibly in humans that impairs insulin action on hepatic glu-
cose production (Muse et al., 2004). Resistin decreases AMPK
phosphorylation (Banerjee et al., 2004; Muse et al., 2004) in
liver. Whether this is critical for the effects of resistin on hepatic
glucose output remains to be determined.
Signaling through α and β adrenergic
receptors activates AMPK
The β adrenergic agonist, isoproterenol, stimulates AMPK ac-
tivity in isolated adipocytes (Moule and Denton, 1998), while α
adrenergic receptors, as well as other G protein-coupled re-
ceptors linked to inositol trisphosphate release via Gq, activate
AMPK in cultured cells (Kishi et al., 2000) and skeletal muscle
(Minokoshi et al., 2002). As discussed above, α adrenergic re-
ceptors in muscle mediate leptin’s effects through the hypo-19
R E V I E Wthalamus and sympathetic nervous system on AMPK activation
and fatty acid oxidation in muscle (Figure 2).
AMPK regulates food intake by integrating hormonal
and nutrient signals in the hypothalamus
Perhaps one of the most exciting recent advances is the dis-
covery that AMPK is a master regulator of food intake. Its activ-
ity in the hypothalamus is modulated by normal physiology,
i.e., fasting increases AMPK activity in the hypothalamus, while
refeeding suppresses it (Figure 3) (Minokoshi et al., 2004).
These effects could result from changes in glucose and insulin
levels, since hyperglycemia and hyperinsulinemia suppress hy-
pothalamic AMPK activity (Minokoshi et al., 2004). Administra-
tion of 2-deoxyglucose, which depletes cellular ATP, activates
hypothalamic AMPK activity (Kim et al., 2004b). Leptin inhibits
AMPK activity specifically in the arcuate and paraventricular
nuclei, and this inhibition is essential for leptin’s anorexigenic
and weight loss effects (Figure 3). The anorexigenic effect of
leptin is mediated in part through melanocortin 4 (MC4) recep-
tor signaling. An agonist for this receptor that inhibits food in-
take also inhibits AMPK activity in the paraventricular hypothal-
amus. Mice lacking the MC4 receptor are hyperphagic and
obese and fail to inhibit AMPK activity in response to either
refeeding or leptin (Minokoshi et al., 2004), suggesting that
MC4 receptors are necessary for the physiologic and hormonal
regulation of AMPK in the paraventricular hypothalamus. ICV
administration of α-lipoic acid, a short chain fatty acid and a
cofactor of mitochondrial respiratory enzymes, also suppresses
hypothalamic AMPK activity and is associated with decreased
food intake and weight loss (Kim et al., 2004b), consistent with a
critical role for hypothalamic AMPK in the central regulation of
energy balance.
On the other hand, orexigenic peptides such as the gut-
derived hormone ghrelin (Andersson et al., 2004) and the neu-
ropeptide agouti-related peptide (Minokoshi et al., 2004) stimu-
late hypothalamic AMPK activity, indicating that this system
functions bidirectionally to regulate both appetite stimulationTable 2. Genetic manipulation of AMPK subunits in mouse models
Model Brief description of phenotype Reference
Total α1 KO No detectable metabolic phenotype Jorgensen, 2004
Total α2 KO Insulin-resistance, increased catecholamine secretion in urine, no effect on muscle Jorgensen, 2004
glucose uptake in response to contraction, increased fat mass following high-fat Viollet, 2003
diet Villena, 2004
Muscle-specific overexpression of α2 dominant- Decreased glucose uptake in skeletal muscle in response to contraction, decreased Mu, 2001
negative (muscle creatine kinase promoter) glucose uptake in heart during ischemia, decreased fatty acid oxidation following Russell, 2004
reperfusion, increased cardiac dysfunction and apoptosis
Cardiac-specific overexpression of α2 dominant- Decreased glucose uptake in heart, increased depletion of ATP, increased left Xing, 2003
negative (α myosin heavy chain promoter) ventricular dysfunction during ischemia
Cardiac-specific overexpression of γ2 wild-type No detectable phenotype observed Arad, 2003
(α myosin heavy chain promoter)
Cardiac-specific overexpression of γ2 N488I Marked cardiac hypertrophy, glycogen accumulation, ventricular preexcitation (similar Arad, 2003
mutant (α myosin heavy chain promoter) to Wolff-Parkinson-White syndrome)
Total γ3 KO Reduced glycogen synthesis following recovery from exercise Barnes, 2004
Skeletal muscle-specific overexpression of γ3 No detectable phenotype observed Barnes, 2004
wild-type (myosin light chain 1 promoter)
Skeletal muscle-specific overexpression of γ3 Elevated level of glycogen in muscle, increased synthesis of glycogen following Barnes, 2004
R225Q mutant (myosin light chain 1 promoter) recovery from exercise, reduced fat accumulation, and insulin-resistance in muscle
following a high-fat diet.
KO = gene knockout mice20and inhibition (Figure 3). The possibility that changes in AMPK
activity can account for the food intake effects is strengthened
by the fact that direct activation of hypothalamic AMPK in-
creases food intake and body weight (Andersson et al., 2004;
Minokoshi et al., 2004), while inhibition of hypothalamic AMPK
decreases food intake and body weight (Kim et al., 2004a; Mi-
nokoshi et al., 2004). These changes can be explained, at least
in part, by alterations in neuropeptide expression in hypothala-
mic neurons (Figure 3 inset) (Minokoshi et al., 2004). Since con-
stitutive activation of hypothalamic AMPK causes leptin resis-
tance (Minokoshi et al., 2004), it will be important to determine
whether AMPK modulation is impaired in leptin-resistant states
such as obesity. If so, altering AMPK signaling or downstream
pathways in the arcuate or paraventricular hypothalamus may
circumvent leptin resistance.
The mechanism by which changes in hypothalamic AMPK
activity alters food intake is unknown. The reduction in hypo-
thalamic AMPK activity in response to leptin was associated
with decreased ACC phosphorylation in one study (Andersson
et al., 2004). Reduced ACC phosphorylation would result in
increased ACC activity leading to increased malonyl CoA levels
which would inhibit CPT1 and hence mitochondrial fatty acid
oxidation (Figure 2). While some studies in which fatty acid
synthase inhibitors were injected ICV in mice suggest that in-
creases in hypothalamic malonyl CoA levels could act as an-
orexigenic signals (Hu et al., 2003; Loftus et al., 2000), this is
controversial. Although the role of malonyl CoA is unclear, di-
rect inhibition of CPT1 in the hypothalamus also has anorexi-
genic effects (Obici et al., 2003), further implicating this path-
way in the regulation of food intake. In future studies it will be
important to determine whether changes in hypothalamic
AMPK activity also modulate energy expenditure and whether
these changes are necessary for the effects of the hypothala-
mic-sympathetic nervous system axis on AMPK activity in pe-
ripheral tissues (Minokoshi et al. 2002).
Transgenic animal models
The AMPK transgenic animal models generated to date have
yielded surprising findings (see Table 2). Deletion of both cata-CELL METABOLISM : JANUARY 2005
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with the embryos dying at w10.5 days post conception (B. Viol-
let, personal communication). Interestingly, this is about the
same stage in development that embryos that are null for the
upstream kinase LKB1 die. Deletion of α1 alone has no detect-
able metabolic phenotype (Jorgensen et al., 2004), whereas
deletion of α2 results in mild insulin-resistance and an insulin
secretory defect (Jorgensen et al., 2004; Viollet et al., 2003).
The glucose intolerance in the α2 knockout (KO) mice is not
due to an inherent defect in skeletal muscle glucose uptake,
but probably results from both impaired insulin action and inhi-
bition of insulin secretion owing to increased catecholamine
levels in the fed state (Viollet et al., 2003). The molecular basis
for this defect is not understood, but it may be due to altered
sympathetic nervous activity, consistent with a regulatory role
of α2 within the CNS. α2 KO mice fed a high-fat diet exhibit
increased body weight and fat mass due to increased size of
preexisting adipocytes, compared to wild-type animals (Villena
et al., 2004).
In addition to α1 and α2 AMPK KO models, many groups
have used a catalytically inactive mutant of α2 that acts as a
dominant-negative form of the kinase to inhibit AMPK in vivo.
Although there are inevitable caveats with genetic models,
some important findings have emerged. Surprisingly, inactiva-
tion of AMPK in skeletal muscle does not have a significant
effect on glucose uptake in response to contraction, although
the effect of AMPK activators, AICA riboside, and hypoxia are
completely abolished (Jorgensen et al., 2004; Mu et al., 2001).
More recently, the increase in GLUT4 expression in response
to exercise and denervation has been reported not to require
AMPK (Holmes et al., 2004). In heart, inactivation of AMPK by
overexpression of dominant-negative α2 significantly reduced
ischaemia-induced glucose uptake, exacerbating ATP deple-
tion and increasing the degree of injury due to apoptosis (Rus-
sell et al., 2004; Xing et al., 2003). In addition, inactivation of
AMPK prevented the increase in fatty acid oxidation following
reperfusion of ischemic hearts (Russell et al., 2004).
To date, there have been no genetic models described for
modulation of the β subunit isoforms of AMPK. Naturally oc-
curring mutations in human γ2 or pig γ3 lead to metabolic ab-
normalities in heart and skeletal muscle, respectively (see
above), and this has led to the generation of several animal
models involving the γ isoforms (Table 2). Cardiac-specific
overexpression of human γ2 harboring a missense mutation
(asparagine 488 to isoleucine, N488I) in mice results in a phe-
notype remarkably similar to that seen in patients with γ2 mu-
tations (Arad et al., 2003). In contrast, overexpression of wild-
type γ2 has no significant effect, indicating that the phenotype
is directly attributable to the mutation (Arad et al., 2003). Skele-
tal muscle-specific overexpression of γ3 harboring a missense
mutation of arginine 225 to glutamine (R225Q) causes a
marked increase in glycogen, similar to the naturally occurring
phenotype in pigs (Barnes et al., 2004), whereas overexpres-
sion of wild-type γ3 had no detectable effect. In mice in which
the γ3 gene was deleted, glycogen resynthesis following exer-
cise was reduced, whereas it was increased in the γ3 mutant
transgenic animals (Barnes et al., 2004). Interestingly, the γ3
mutant transgenic mice, but not the γ3 KO mice, were pro-
tected from excess fat accumulation and insulin resistance in
skeletal muscle when fed a high-fat diet, implying that γ3 may
play a role in substrate utilization in skeletal muscle (Barnes etCELL METABOLISM : JANUARY 2005al., 2004). At present, the effect of mutations in γ2 and γ3 on
AMPK activity in vivo as well as the molecular basis for altered
heart and skeletal muscle metabolism is unclear. Whether the
mutations increase basal AMPK activity (Arad et al., 2002; Mi-
nokoshi et al., 2004) is controversial (see above), but if they do,
the high glycogen content caused by these mutations might
result from a persistently elevated glucose uptake. Thus, fur-
ther studies in these transgenic models will be important for
understanding the role of specific AMPK subunit isoforms and
naturally occurring mutations in metabolism.
Upstream kinases in the AMPK cascade
Although it has been known for over 25 years that AMPK is the
downstream component of a protein kinase cascade (Ingebrit-
sen et al., 1978) the identity of the upstream kinase (AMPKK)
remained elusive until very recently. In the intervening period,
however, the major regulatory phosphorylation site was iden-
tified as Thr172 within the (α) catalytic subunit of AMPK (Haw-
ley et al., 1996). This enabled a number of studies to demon-
strate that phosphorylation of Thr172 is essential for activation
of AMPK and that the degree of phosphorylation of Thr172 cor-
relates with AMPK activity. Thus, to understand the regulation
of AMPK in vivo, identification of the upstream kinase responsi-
ble for phosphorylation of Thr172 is critical.
A vital breakthrough in the search for upstream kinases came
from studies identifying three closely related yeast kinases that
phosphorylate and activate SNF1 in vitro (Hong et al., 2003;
Sutherland et al., 2003). These kinases, Elm1, Pak1, and Tos3,
appear to have overlapping and redundant functions, since de-
letion of all three kinases is required to abolish SNF1 activity in
vivo and confer a phenotype similar to a snf1 mutant pheno-
type (Hong et al., 2003; Sutherland et al., 2003). The most
closely related protein kinases to Elm1, Pak1, and Tos3 in
the human genomic database are members of the calmodu-
lin-dependent protein kinase kinase (CAMKK) family, closely
followed by the tumor suppressor LKB1. Previous studies
showed that AMPKK activity was not dependent on calmodulin
or calcium (Hawley et al., 1995), thus leaving LKB1 as a strong
contender for the elusive AMPKK.
At first, LKB1 appeared an unlikely candidate for AMPKK.
Mutations in the LKB1 gene cause a rare hereditary form of
cancer, termed Peutz-Jeghers syndrome (PJS) (Jenne et al.,
1998), a role not obviously related to the known functions of
AMPK. PJS is characterized by the development of multiple
hamartomatous polyps in the gastrointestinal tract combined
with pigmentation of the mucous membranes. Nearly 100 dif-
ferent LKB1 mutations have been identified in patients with
PJS, and the majority of these are predicted to inactivate the
kinase, although this has not been tested (Boudeau et al.,
2003b). Interestingly, LKB1, like AMPK, is a heterotrimer, re-
quiring two other proteins, mouse protein 25 (MO25) and
STE20-related adaptor protein (STRAD), for catalytic activity.
STRAD is a pseudokinase while MO25 stabilizes the interaction
of LKB1 and STRAD (Boudeau et al., 2003a). In addition to
activating LKB1, binding of MO25 and STRAD appears to lo-
calize LKB1 in the cytoplasm (Boudeau et al., 2003a).
Convincing evidence that LKB1 is a physiologically relevant
AMPK kinase came from the demonstration that (1) the AMPKK
activity purified from rat liver corresponds to LKB1 (Hawley et
al., 2003; Woods et al., 2003) and (2) in cells lacking LKB1,
AMPK activity is dramatically reduced compared to cells ex-21
R E V I E WFigure 4. Proposed model for dual regulation of
TSC-mTOR-S6Kinase pathway by AMPK and insu-
lin-PI3K signaling: Potential role in insulin sensitivity
and the risk for obesity and type 2 diabetes
The activity of the TSC-mTOR-S6Kinase pathway is
the product of the integration of signals activating the
PI3K/Akt signaling (e.g., insulin) and activating the
AMPK pathway (e.g., exercise, leptin, adiponectin, or
hypoxia). TSC controls the activity of the mTOR-
S6Kinase signaling pathway by serving as a GTPase
activating protein for the small protein Ras-like
GTPase Rheb (Ras homolog enriched in brain).
Once activated, TSC increases Rheb-GDP levels.
Since mTOR is activated by increases in Rheb-GTP
levels, this decreases mTOR activity. TSC activity is
regulated inversely by AMPK and PI3K/Akt path-
ways. Activation of the PI3K/Akt pathway leads to
inhibition of TSC activity and thus, activation of the
mTOR pathway. In contrast, activation of AMPK ac-
tivates TSC, thereby inhibiting the mTOR pathway.
However, mTOR activity may also be directly inhib-
ited by AMPK. Regulation of the mTOR-S6K1 path-
way by AMPK may affect insulin sensitivity by mod-
ulating the phosphorylation and amount of IRS.
Indeed, AMPK, by inactivating mTOR, decreases
S6K1 activity, which results in decreased serine
phosphorylation (pS) of IRS and increased IRS-
dependent signaling. On the other hand, chronic ac-
tivation of the mTOR-S6K pathway, e.g., by nutrient
excess, results in reduced IRS tyrosine phosphory-
lation (pY) and increased serine phosphorylation
(pS). These changes may reduce downstream insulin signaling and the metabolic and transcriptional effects of insulin. Alterations in the downstream biologic effects
modulate the risk for obesity and type 2 diabetes. (Modified from Patti and Kahn, 2004).pressing LKB1, and AMPK is not activated by stimuli which
normally activate it (Hawley et al., 2003; Shaw et al., 2004;
Woods et al., 2003). Perplexingly, the activity of LKB1 itself is
not regulated directly by stimuli that activate AMPK, either in
cells (Lizcano et al., 2004; Woods et al., 2003) or in skeletal
muscle where there is no effect of contraction (Sakamoto et
al., 2004), nor is it activated directly by AMP (Hawley et al.,
2003; Woods et al., 2003). LKB1, therefore, appears to be
“constitutively active,” and the regulation of AMPK phosphory-
lation is presumably mediated via effects on AMPK itself, rather
than on LKB1. It is possible that LKB1 is regulated indirectly,
for instance, by altered association with MO25 and/or STRAD
and/or changes in its subcellular localization.
The finding that LKB1 is an AMPK kinase yielded a double
breakthrough as it not only provided identification of AMPKK,
but it also provided a downstream target for LKB1, which pre-
viously had no identified physiological target. Recently, it was
shown that LKB1 can activate 11 AMPK-related kinases by
phosphorylation of a threonine residue equivalent to Thr172 in
AMPK (Lizcano et al., 2004). This suggests that LKB1 may act
as a master upstream kinase and clearly raises the possibility
that some of the functions of LKB1 are mediated by the AMPK-
related kinases, rather than AMPK itself. Currently, however,
the physiological role of the AMPK-related kinases and of
LKB1 in regulating these kinases is not clear. In yeast, there
are three upstream AMPK/SNF1 kinase cascades, and, naively,
one might anticipate the same number or more in the more
complex mammalian system. This may be the case, since
AMPK has some activity and is weakly phosphorylated on
Thr172 in LKB1−/− cells (Hawley et al., 2003). At present, the22identity of the kinase(s) that phosphorylates AMPK in the ab-
sence of LKB1 remains unknown.
Integration of AMPK and insulin signaling pathways
and modulation of the risk for obesity and diabetes
Recent studies suggest that the mTor-S6 kinase 1 (S6K1) path-
way may play an important role in regulation of insulin sensitiv-
ity and adiposity (Figure 4). S6K1−/− mice are protected against
age- and high fat diet-induced obesity and insulin resistance
due to increased energy expenditure associated with en-
hanced tissue mitochondrial content (Um et al., 2004). S6K1
phosphorylates IRS proteins on serine residues, which de-
creases tyrosine phosphorylation and insulin signaling (Har-
rington et al., 2004). In addition, S6K1 activation decreases IRS
protein levels through alterations in transcription and protein
degradation (Harrington et al., 2004; Shah et al., 2004). Since
AMPK inhibits phosphorylation of S6K1 on Thr389, and, thus,
its activation (Kimura et al., 2003), this could provide a molecu-
lar mechanism by which AMPK increases insulin sensitivity in
addition to its effects on lipid metabolism.
S6K1 is regulated by an upstream cascade involving the tu-
mor suppressor products Tuberous Sclerosis Complex (TSC)
proteins 1 and 2 that control the activity of the upstream kinase
mTOR (Hay and Sonenberg, 2004) (Figure 4). TSC serves as
a GTPase activating protein for the small GTPase Rheb (Ras
homolog enriched in brain). Once activated, TSC increases
Rheb-GDP levels, which decreases mTOR activity and S6K1
activation (Figure 4). TSC activity is regulated by both AMPK
and PI3K/Akt pathways (Hay and Sonenberg, 2004). Activation
of the PI3K/Akt pathway inhibits TSC activity, and, thus, acti-
vates the mTOR pathway. In contrast, phosphorylation of TSCCELL METABOLISM : JANUARY 2005
R E V I E Wby AMPK activates TSC, leading to inhibition of the mTOR
pathway. AMPK may also inhibit mTOR activity by direct phos-
phorylation (Cheng et al., 2004). Thus, we propose that AMPK
may affect insulin sensitivity by modulating the mTOR-S6K
pathway, which in turn alters phosphorylation and protein
levels of IRS (Harrington et al., 2004). Inactivation of TSC lead-
ing to activation of mTor-S6K signaling results in a negative
feedback program that attenuates insulin signaling through IRS
and PI3K and, hence, causes insulin resistance (Harrington et
al., 2004; Shah et al., 2004). AMPK may function on both TSC
and mTor directly to prevent impaired insulin signaling and ob-
viate the metabolic changes that increase the risk for obesity
and diabetes (Figure 4).
Summary and future directions
Major advances now reveal that the evolutionarily conserved
cellular fuel gauge, AMPK, acts as a master regulator of metab-
olism not only at the cellular level but also at the whole body
level. As the complexity has broadened, concepts that once
had almost the status of dogma have now been challenged,
such as the idea that AMPK plays a key role in contraction-
stimulated glucose transport. The nature of the effects of
AMPK on glycogen synthesis is also increasingly complex due
to multiple regulatory factors. Other key challenges include (1)
identifying the molecules that lie upstream and downstream of
AMPK in the hypothalamic regulation of food intake (Figure 3),
(2) determining the mechanisms by which the naturally occur-
ring mutations in the γ subunits produce alterations in cardiac
or skeletal muscle function (Table 2), and (3) determining the
physiological significance of the potential effects of AMPK on
the insulin signaling cascade (Figure 4).
The identification of LKB1 as an upstream kinase in the
AMPK cascade is a long-awaited advance in the field. Now it
will be important to determine the full extent of the role of LKB1
in regulating AMPK. Similarly, we need to determine what func-
tions of LKB1 are mediated by AMPK and whether these are
involved in cell proliferation effects such as those seen in PJS.
An attractive hypothesis would link nutrient regulation of me-
tabolism with cell proliferation, and the connection between
LKB1 and AMPK is an obvious link. Identification of other po-
tential upstream AMPK kinases will also be critical, as these
could provide alternative pathways for regulation of AMPK,
perhaps through different signaling mechanisms, e.g., different
stimuli, or by tissue-specific expression of the different up-
stream kinases.
Recent discoveries demonstrating that the AMPK cascade
plays a central role in the regulation of body weight, systemic
glucose homeostasis, lipid metabolism, mitochondrial biogen-
esis, and possibly even insulin signaling make it an attractive
therapeutic target. Indeed, an AMPK activator has therapeutic
effects in obese and diabetic rodents and in humans, with
some side effects (reviewed in Musi and Goodyear, 2002). The
challenge is high, since AMPK’s effects are widespread. Fur-
thermore, a therapeutic agent would ideally activate AMPK in
peripheral tissues (to increase fatty acid oxidation and glucose
uptake and reduce gluconeogenesis) while inhibiting it in the
hypothalamus (to reduce food intake and body weight). Re-
search in this field will undoubtedly continue to elucidate the
intricate biology of energy balance and provide critical informa-CELL METABOLISM : JANUARY 2005tion to understand the pathogenesis of obesity and type 2 dia-
betes.
Supplemental Data
Supplemental Data includes one table and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/1/1/15/DC1/.
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